Viking Therapeutics Inc VKTX

NAS: VKTX | ISIN: US92686J1060   30/04/2025
28,87 USD (+3,33%)
(+3,33%)   30/04/2025

23 april 2025 · Viking Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update · Persbericht

16 april 2025 · Viking Therapeutics to Report Financial Results for First Quarter 2025 on April 23, 2025 · Persbericht

26 maart 2025 · Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity · Persbericht

11 maart 2025 · Viking Therapeutics Signs Broad Manufacturing Agreement With CordenPharma to Support Commercialization of VK2735 · Persbericht

4 maart 2025 · Viking Therapeutics to Participate at Upcoming Investor Conferences · Persbericht

28 augustus 2024 · Viking Therapeutics to Participate at Morgan Stanley 22nd Annual Global Healthcare Conference · Persbericht

24 juli 2024 · Viking Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

17 juli 2024 · Viking Therapeutics to Report Financial Results for Second Quarter 2024 on July 24, 2024 · Persbericht

24 juni 2024 · Viking Therapeutics Presents Preclinical Data on Novel Dual Amylin and Calcitonin Receptor Agonists at 84th Scientific Sessions of the American Diabetes Association · Persbericht

4 juni 2024 · Viking Therapeutics Announces Positive 52-Week Histologic Data from Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH) · Persbericht

30 mei 2024 · Viking Therapeutics to Participate at Upcoming Investor Conferences · Persbericht

24 april 2024 · Viking Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update · Persbericht

17 april 2024 · Viking Therapeutics to Report Financial Results for First Quarter 2024 on April 24, 2024 · Persbericht

26 maart 2024 · Viking Therapeutics Announces Results from Phase 1 Clinical Trial of Oral Tablet Formulation of Dual GLP-1/GIP Receptor Agonist VK2735 · Persbericht

4 maart 2024 · Viking Therapeutics Announces Closing of Public Offering of Common Stock Including Full Exercise of Underwriters' Option to Purchase Additional Shares · Persbericht

29 februari 2024 · Viking Therapeutics Announces Pricing of $550 Million Public Offering of Common Stock · Persbericht

27 februari 2024 · Viking Therapeutics Announces Proposed Public Offering of Common Stock · Persbericht

27 februari 2024 · Viking Therapeutics Announces Positive Top-Line Results from Phase 2 VENTURE Trial of Dual GLP-1/GIP Receptor Agonist VK2735 in Patients with Obesity · Persbericht

7 februari 2024 · Viking Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update · Persbericht

31 januari 2024 · Viking Therapeutics to Report Financial Results for Fourth Quarter and Year-End 2023 on February 7, 2024 · Persbericht

Mijn selecties